

Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2020-2025

<https://marketpublishers.com/r/PB104A60A15EN.html>

Date: April 2020

Pages: 269

Price: US\$ 4,250.00 (Single User License)

ID: PB104A60A15EN

Abstracts

Get an in-depth analysis of COVID-19 impact on the global premature ejaculation market.

The premature ejaculation therapeutics market is expected to grow at a CAGR of over 8% during the period 2019–2025.

The global premature ejaculation (PE) therapeutics market is expected to grow at a steady CAGR during the forecast period. The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally. PE is the most prevalent sexual dysfunction among men world over. With the presence of a single approved oral drug, the PE therapeutics market is dominated by off-label drugs, generic versions of patent expired drugs, and OTC formulations, both regionally as well as globally. The increasing demand for several off-label and generic drugs is a primary factor driving the growth of the market. The treatment with off-label drugs belonging to SSRIs and topical formulations has revolutionized the treatment approach. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs and PDE5 inhibitors and OTC topical creams/sprays for treatment. Therefore, the demand for such drugs is likely to increase at a steady rate globally.

Another advance is the advent of metered-dose delivery systems. Several OTC anesthetic sprays are formulated to deliver the drug through a metered-dose administration. Metered-dose delivery systems deliver lidocaine and prilocaine in base form without organic solvents. Such drugs can be easily removed before vaginal penetration, thus circumventing the need for a condom that most patients find uncomfortable. Hence, such advanced formulations are likely to boost the future growth of the global PE therapeutics market

The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period:

High Demand for Topical Drug Therapies for PE Treatment

Low Effectiveness of Non-pharmacological PE Treatment

Increasing Awareness Campaigns and Initiatives for PE Treatment

Advances in PE Drug Formulation Technology

The study considers the present scenario of the premature ejaculation therapeutics market and its market dynamics for the period 2019-2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Premature Ejaculation Therapeutics Market: Segmentation

This research report offers a detailed segmentation by drugs, ROA, and geography. The SSRIs segment is likely to retain its market dominance during the forecast period. SSRIs are considered as effective drugs for the treatment of PE, and they majorly include paroxetine, sertraline, fluoxetine, citalopram, escitalopram, and dapoxetine. Several evidence-based studies have demonstrated the safety and efficacy of SSRIs in delaying ejaculation, which ensures their role as first-line agents for the treatment of lifelong and acquired PE. The growth of the segment is likely to be facilitated by an increase in the number of countries gaining approval for the use of Priligy. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide.

The increase in the share of the PDE5 inhibitors segment can be mainly attributed to the brand value of existing PDE5 inhibitor drugs, which facilitate high uptake among patients, especially for self-management. Anesthetic agents have proved effective and are generally tolerated for patients with PE. Several topical anesthetics are inexpensive and readily available from pharmacies, thereby allowing them an easy medication to buy. The segment is likely to witness higher CAGR during the forecast period than other drug therapies. The expected launch of new licensed/unlicensed OTC products

worldwide is the prime factor enhancing growth.

Oral therapeutics consists of tablets, capsules, solutions, and suspensions. Several oral agents, specifically SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of PE. Hence, several HCPs are recommending oral therapeutics as a primary treatment option to manage premature ejaculation. A daily dose of oral therapies has exhibited improved and enhanced efficacy over topical therapies. Therefore, the demand for oral therapeutics is increasing at a steady-state worldwide. Moreover, the growing pervasiveness of PE and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.

Topical medications refer to the drugs that are applied to the skin and include creams, gels, sprays, powders, emulsion, solutions, and ointments. These drugs are often used as “a needed option” for efficient management of PE and erectile dysfunction. Therefore, the segment accounts for a smaller share than oral therapeutics. Easy availability of several topical medicines at multiple sales channels acts as one of the key factors, which boosts the product uptake of topical therapies in the vast majority of patients.

Market Segmentation by Drug Class

SSRIs

PDE5 Inhibitors

Anesthetic Agents

Others

Market Segmentation by ROA

Oral PE therapeutics

Topical PE therapeutics

Insights by Geography

North America is the major revenue contributor to the global premature ejaculation therapeutics market. The presence of a large disease population, coupled with better access to healthcare, especially OTC drugs, and increased focus on sexual wellness products is the primary factor for high shares. The strong presence of key vendors is also another reason for high product uptake in the region.

The presence of major vendors, better disease awareness, high healthcare spending on sexual wellbeing is the primary factor for high market share in this region. Germany, the UK, France, Italy, and Spain are the major revenue contributors. The increasing treatment-seeking population will mainly drive the market in Europe due to improved PE awareness and increased patient focus on healthy sexual well-being.

A low treatment-seeking population associated with social stigma in select regions, lack of awareness, and comparatively less access to healthcare services, especially in developing countries, are few factors that limit the growth of the market in this region. Japan, India, China, Australia, and South Korea are the major revenue contributors in the region.

Market Segmentation by Geography

Europe

Spain

Germany

Italy

France

UK

North America

US

Canada

APAC

South Korea

China

Japan

Australia

India

Latin America

Brazil

Argentina

Mexico

MEA

Turkey

Saudi Arabia

South Africa

Iran

Insights by Vendors

The global premature ejaculation therapeutics market is fairly fragmented and is characterized by the presence of both pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents. Companies offering topical anesthetic drug formulations are gaining widespread popularity than manufacturers offering oral PE therapeutics. Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline are also being used as off-label drugs. Therefore, these global players

have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan and are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs. However, due to their high cost, a broad majority of physicians worldwide are recommending low-cost generic versions of these popular prescription drugs. Therefore, the market has witnessed the entry of many generic manufacturers offering generic drugs of the patent expired drugs at a low price.

Key Vendors

Absorption Pharmaceuticals

Innovus Pharmaceuticals

Pfizer

Plethora Solutions Holdings

Other Vendors

Bayer

Eli Lilly and Company

GlaxoSmithKline

MidasCare

Momentum Management

Pound International

Reckitt Benckiser Group

Recordati

Royalty Pharma

Shibari

The Menarini Group

Key Market Insights

The analysis of the premature ejaculation therapeutics market provides sizing and growth opportunities for the period 2020–2025.

Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.

Includes a detailed analysis of growth drivers, challenges, and investment opportunities.

Delivers a complete overview of segments and the regional outlook of the market.

Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.

Contents

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.2 Base Year

4.3 Scope of The Study

4.3.1 Market Segmentation by Geography

5 REPORT ASSUMPTIONS & CAVEATS

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 Premature Ejaculation: An Overview

7.1.1 Definition

7.1.2 Disease Overview

7.1.3 Classification of Premature Ejaculation

7.1.4 Symptoms of PE

7.1.5 Etiology of Premature Ejaculation

7.1.6 Epidemiology

7.2 ISSN Guidelines On Premature Ejaculation

7.2.1 Disease Assessment

7.2.2 Treatment Options For Pe

8 CLINICAL TRIAL LANDSCAPE

8.1 Overview

8.1.1 Subjects Selection Criteria for PE Clinical Trials

8.1.2 Clinical Trial Data Evaluation Considerations

8.1.3 Clinical Trial Design Considerations for PE

8.2 Clinical Trial Endpoints

9 PIPELINE LANDSCAPE

9.1 Overview

9.2 Key Pipeline Drug candidates

9.3 Key Pipeline Molecules

9.3.1 Epelsiban

9.3.2 IX-01

9.3.3 DA-8031

9.3.4 NH02D

9.4 Terminated/Withdrawn Drug Candidates

10 MARKET OPPORTUNITIES & TRENDS

10.1 High Demand for Topical Drug Therapies for PE Treatment

10.2 Presence of High Unmet Demand

10.3 Advancements in PE Drug Formulation Technology

11 MARKET GROWTH ENABLERS

11.1 Rising Prevalence/Incidence of PE

11.2 Wide Accessibility of OTC Drugs & General Off-label Drugs for PE

11.3 Low effectiveness of Non-pharmacological PE Treatment

11.3.1 Major Drawbacks of Non-Pharmacological Treatments

11.4 Increasing Awareness Campaigns & Initiatives for PE Treatment

12 MARKET RESTRAINTS

12.1 Availability of Alternative Treatment Options for PE

12.2 Low Treatment-Seeking Patient Pool

12.3 Adverse Effects of PE Therapeutics

12.4 Clinical Trial Withdrawals/Terminations & Inactive Clinical Studies

13 MARKET LANDSCAPE

- 13.1 Market Overview
- 13.2 Market Size & Forecast
- 13.3 Five Forces Analysis
 - 13.3.1 Threat of New Entrants
 - 13.3.2 Bargaining Power of Suppliers
 - 13.3.3 Bargaining Power of Buyers
 - 13.3.4 Threat of Substitutes
 - 13.3.5 Competitive Rivalry

14 DRUG CLASS

- 14.1 Market Snapshot & Growth Engine
- 14.2 Market Overview
- 14.3 SSRIs
 - 14.3.1 Market Overview
 - 14.3.2 Market Size & Forecast
- 14.4 PDE5 Inhibitors
 - 14.4.1 Market Overview
 - 14.4.2 Market Size & Forecast
- 14.5 Anesthetic Agents
 - 14.5.1 Market Overview
 - 14.5.2 Market Size & Forecast
- 14.6 Others
 - 14.6.1 Market Overview
 - 14.6.2 Market Size & Forecast

15 ROUTE OF ADMINISTRATION

- 15.1 Market Snapshot & Growth Engine
- 15.2 Market Overview
- 15.3 Oral
 - 15.3.1 Market Overview
 - 15.3.2 Market Size & Forecast
- 15.4 Topical
 - 15.4.1 Market Overview
 - 15.4.2 Market Size & Forecast

16 GEOGRAPHY

16.1 Market Snapshot & Growth Engine

16.2 Overview

17 NORTH AMERICA

17.1 Market Overview

17.2 Market Size & Forecast

17.3 Drug Class Segmentation

17.3.1 Market Snapshot & Growth Engine

17.4 KEY COUNTRIES

17.4.1 US: Market Size & Forecast

17.4.2 Canada: Market Size & Forecast

18 EUROPE

18.1 Market Overview

18.2 Market Size & Forecast

18.3 Drug Class Segmentation

18.3.1 Market Snapshot & Growth Engine

18.4 Key Countries

18.4.1 Germany: Market Size & Forecast

18.4.2 UK: Market Size & Forecast

18.4.3 France: Market Size & Forecast

18.4.4 Italy: Market Size & Forecast

18.4.5 Spain: Market Size & Forecast

19 APAC

19.1 Market Overview

19.2 Market Size & Forecast

19.3 Drug Class Segmentation

19.3.1 Market Snapshot & Growth Engine

19.4 Key Countries

19.4.1 Japan: Market Size & Forecast

19.4.2 India: Market Size & Forecast

19.4.3 China: Market Size & Forecast

19.4.4 Australia: Market Size & Forecast

19.4.5 South Korea: Market Size & Forecast

20 LATIN AMERICA

20.1 Market Overview

20.2 Market Size & Forecast

20.3 Drug Class Segmentation

20.3.1 Market Snapshot & Growth Engine

20.4 Key Countries

20.4.1 Brazil: Market Size & Forecast

20.4.2 Mexico: Market Size & Forecast

20.4.3 Argentina: Market Size & Forecast

21 MIDDLE EAST & AFRICA

21.1 Market Overview

21.2 Market Size & Forecast

21.3 Drug Class Segmentation

21.3.1 Market Snapshot & Growth Engine

21.4 Key Countries

21.4.1 Turkey: Market Size & Forecast

21.4.2 Saudi Arabia: Market Size & Forecast

21.4.3 South Africa: Market Size & Forecast

21.4.4 Iran: Market Size & Forecast

22 COMPETITIVE LANDSCAPE

22.1 Competition Overview

22.2 Market Share Analysis

22.2.1 Absorption Pharmaceuticals

22.2.2 Innovus Pharmaceuticals

22.2.3 Pfizer

22.2.4 Plethora Solutions

23 KEY COMPANY PROFILES

23.1 Absorption Pharmaceuticals

23.1.1 Business Overview

23.1.2 Product Offerings

- 23.1.3 Key Strategies
- 23.1.4 Key Strengths
- 23.1.5 Key Opportunities
- 23.2 Innovus Pharmaceuticals
 - 23.2.1 Business Overview
 - 23.2.2 Product Offerings
 - 23.2.3 Key Strategies
 - 23.2.4 Key Strengths
 - 23.2.5 Key Opportunities
- 23.3 Pfizer
 - 23.3.1 Business Overview
 - 23.3.2 Product Offerings
 - 23.3.3 Key Strategies
 - 23.3.4 Key Strengths
 - 23.3.5 Key Opportunities
- 23.4 Plethora Solutions Holdings
 - 23.4.1 Business Overview
 - 23.4.2 Product Offerings
 - 23.4.3 Key Strategies
 - 23.4.4 Key Strengths
 - 23.4.5 Key Opportunities

24 OTHER PROMINENT VENDORS

- 24.1 Bayer
 - 24.1.1 Business Overview
 - 24.1.2 Product Offerings
 - 24.1.3 Key Strategies
 - 24.1.4 Key Strengths
 - 24.1.5 Key Opportunities
- 24.2 Eli Lilly and Company
 - 24.2.1 Business Overview
 - 24.2.2 Product Offerings
 - 24.2.3 Key Strategies
 - 24.2.4 Key Strengths
 - 24.2.5 Key Opportunities
- 24.3 GlaxoSmithKline
 - 24.3.1 Business Overview
 - 24.3.2 Product Offerings

- 24.3.3 Key Strategies
- 24.3.4 Key Strengths
- 24.3.5 Key Opportunities
- 24.4 MidasCare
 - 24.4.1 Business Overview
 - 24.4.2 Product Offerings
 - 24.4.3 Key Strategies
 - 24.4.4 Key Strengths
 - 24.4.5 Key Opportunities
- 24.5 Momentum Management
 - 24.5.1 Business Overview
 - 24.5.2 Product Offerings
 - 24.5.3 Key Strategies
 - 24.5.4 Key Strengths
 - 24.5.5 Key Opportunities
- 24.6 Pound International
 - 24.6.1 Business Overview
 - 24.6.2 Product Offerings
 - 24.6.3 Key Strategies
 - 24.6.4 Key Strengths
 - 24.6.5 Key Opportunities
- 24.7 Reckitt Benckiser Group
 - 24.7.1 Business Overview
 - 24.7.2 Product Offerings
 - 24.7.3 Key Strategies
 - 24.7.4 Key Strengths
 - 24.7.5 Key Opportunities
- 24.8 Recordati
 - 24.8.1 Business Overview
 - 24.8.2 Product Offerings
 - 24.8.3 Key Strategies
 - 24.8.4 Key Strengths
 - 24.8.5 Key Opportunities
- 24.9 Royalty Pharma
 - 24.9.1 Business Overview
 - 24.9.2 Product Offerings
 - 24.9.3 Key Strategies
 - 24.9.4 Key Strengths
 - 24.9.5 Key Opportunities

24.10 Shibari

24.10.1 Business Overview

24.10.2 Product Offerings

24.10.3 Key Strategies

24.10.4 Key Strengths

24.10.5 Key Opportunities

24.11 The Menarini Group

24.11.1 Business Overview

24.11.2 Product Offerings

24.11.3 Key Strategies

24.11.4 Key Strengths

24.11.5 Key Opportunities

25 REPORT SUMMARY

25.1 Key Takeaways

25.2 Strategic Recommendations

26 QUANTITATIVE SUMMARY

26.1 Drug Class

26.2 Route of Administration (RoA)

26.3 Geography

27 APPENDIX

27.1 Abbreviations

List Of Exhibits

LIST OF EXHIBITS

- Exhibit 1 Segmentation of Global Premature Ejaculation Therapeutics Market
- Exhibit 2 Market Size Calculation Approach 2019
- Exhibit 3 Characteristics Associated with PE
- Exhibit 4 Classification of PE
- Exhibit 5 ISSM Classification of PE
- Exhibit 6 Broader Classification of PE
- Exhibit 7 Major PE Types
- Exhibit 8 Differentiation of Symptoms in Different PE Sub-types
- Exhibit 9 Most Common Psychological Causes for PE
- Exhibit 10 Common Causative Factors for PE
- Exhibit 11 PE Prevalence Rate across Geographies
- Exhibit 12 ISSN Recommended Drug Classes for PE Treatment
- Exhibit 13 ISSN Recommended Drug Class for the Treatment of PE
- Exhibit 14 Key Considerations of PE Clinical Trials
- Exhibit 15 Clinical Trial Considerations
- Exhibit 16 Key Primary/Secondary Endpoints in PE Clinical Trials
- Exhibit 17 Key Hurdles in Research & Innovation of Breakthrough PE Drugs
- Exhibit 18 Impact of High Demand for Topical Drug Therapies for PE Treatment
- Exhibit 19 Available Topical Forms of PE Topical Therapies
- Exhibit 20 Benefits of Topical Drug Delivery System for PE
- Exhibit 21 Impact of Presence of High Unmet Demand
- Exhibit 22 Impact of Advancements in PE Drug Formulation Technology
- Exhibit 23 Impact of Rising Prevalence/Incidence of PE
- Exhibit 24 Prevalence Rate of PE in Different Region
- Exhibit 25 Comparison of Prevalence Rates of PE and ED in Different Age Groups (%)
- Exhibit 26 Number of Men with Premature Ejaculation in US and EU (million)
- Exhibit 27 Global Diabetes Prevalence by Region 2015–2040 (million)
- Exhibit 28 Global Cancer Incidence 2018
- Exhibit 29 Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)
- Exhibit 30 Increase in Global ED Prevalence 1995–2025 (million)
- Exhibit 31 Impact of Wide Accessibility of OTC Drugs & General Off-label Drugs for PE
- Exhibit 32 Popular Therapeutics Available for Premature Ejaculation Treatment in Market
- Exhibit 33 PE OTC Drugs Marketing Channels

- Exhibit 34 Impact of Low Effectiveness of Non-pharmacological PE Treatment
- Exhibit 35 Effectiveness of Pharmacotherapy for PE Treatment
- Exhibit 36 Major Drawbacks of Non-pharmacological PE Treatments
- Exhibit 37 Impact of Increasing Awareness Campaigns & Initiatives for PE Treatment
- Exhibit 38 Impact of Availability of Alternative Treatment Options for PE
- Exhibit 39 Popular Alternative Methods for PE Treatment
- Exhibit 40 Impact of Low Treatment-Seeking Patient Pool
- Exhibit 41 Number of Men with PE 2018 (million)
- Exhibit 42 Key Factors Restricting PE Treatment Adoption
- Exhibit 43 Major Surveys to Indicate Low PE Treatment Seeking Population
- Exhibit 44 South Korean Survey Results on Urologists' PE Treatment Rates Per Week in 2012 (%)
- Exhibit 45 Impact of Adverse Effects of PE Therapeutics
- Exhibit 46 Common Adverse Effects of Drugs Recommended for PE
- Exhibit 47 Impact of Clinical Trial Withdrawals/Terminations & Inactive Clinical Studies
- Exhibit 48 Key Common Challenges Associated with Clinical Trial Withdrawals/Terminations
- Exhibit 49 Global Premature Ejaculation Therapeutics Market Snapshot
- Exhibit 50 Global Premature Ejaculation Therapeutics Market 2019–2025 (\$ million)
- Exhibit 51 Global Premature Ejaculation Therapeutics Market by Geography
- Exhibit 52 Global Premature Ejaculation Therapeutics Market by Drug Class
- Exhibit 53 Global Premature Ejaculation Therapeutics Market by ROA
- Exhibit 54 Five Forces Analysis 2019
- Exhibit 55 Incremental Growth by Drug Class 2019 & 2025
- Exhibit 56 Global Premature Ejaculation Therapeutics Market by Drug Class
- Exhibit 57 Global Premature Ejaculation Therapeutics Market by Drug Class: Incremental Growth
- Exhibit 58 Global Premature Ejaculation Therapeutics Market by Drug Class: Absolute Growth
- Exhibit 59 Global Premature Ejaculation Therapeutics Market by Drug Class 2019?2025 (\$ million)
- Exhibit 60 Global Premature Ejaculation Therapeutics Market by Drug Class 2019?2025 (%)
- Exhibit 61 Common SSRIs for Treating PE
- Exhibit 62 Global PE Therapeutics Market by SSRIs: Incremental & Absolute Growth Comparison
- Exhibit 63 Comparison of Varying Efficacy Rates of Off-label SSRIs
- Exhibit 64 Global SSRIs PE Therapeutics Market 2019–2025 (\$ million)
- Exhibit 65 Global PE Therapeutics Market by PDE5 Inhibitors: Incremental & Absolute

Growth Comparison

Exhibit 66 Major PDE5i Drug Brands as Off-label PE Medications

Exhibit 67 Global PDE5 Inhibitors PE Therapeutics Market 2019–2025 (\$ million)

Exhibit 68 Global PE Therapeutics Market by Anesthetic Agents: Incremental & Absolute Growth Comparison

Exhibit 69 Common Active Ingredients in Topical Anesthetic Formulations

Exhibit 70 Global Anesthetic PE Therapeutics Market 2019–2025 (\$ million)

Exhibit 71 Global PE Therapeutics Market by Others Drugs: Incremental & Absolute Growth Comparison

Exhibit 72 Several Drug Classes Used for Treating Premature Ejaculation

Exhibit 73 Global Others Drug PE Therapeutics Market 2019–2025 (\$ million)

Exhibit 74 Incremental Growth by ROA 2019 & 2025

Exhibit 75 Global Premature Ejaculation Therapeutics Market by ROA

Exhibit 76 Global Premature Ejaculation Therapeutics Market by ROA: Incremental Growth

Exhibit 77 Global Premature Ejaculation Therapeutics Market by ROA: Absolute Growth

Exhibit 78 Global Premature Ejaculation Therapeutics Market by ROA 2019?2025 (\$ million)

Exhibit 79 Global Premature Ejaculation Therapeutics Market by ROA 2019?2025 (%)

Exhibit 80 Oral Premature Ejaculation Treatment Market: Incremental & Absolute Growth

Exhibit 81 Major Oral Therapeutics Recommended for PE

Exhibit 82 Advantages of Oral PE Drugs

Exhibit 83 Global Oral PE Therapeutics Market 2019–2025 (\$ million)

Exhibit 84 Available Topical Forms of PE Topical Therapies

Exhibit 85 Global PE Therapeutics Market by Topical ROA: Incremental & Absolute Growth

Exhibit 86 Benefits of Topical PE Drugs

Exhibit 87 Global Topical PE Therapeutics Market 2019–2025 (\$ million)

Exhibit 88 Incremental Growth by Geography 2019 & 2025

Exhibit 89 Global Premature Ejaculation Therapeutics Market by Geography

Exhibit 90 Global Premature Ejaculation Therapeutics Market by Geography 2019: Key Countries (\$ million)

Exhibit 91 Global Premature Ejaculation Therapeutics Market by Geography: Incremental Growth

Exhibit 92 Global Premature Ejaculation Therapeutics Market by Geography: Absolute Growth

Exhibit 93 Global Premature Ejaculation Therapeutics Market by Geography 2019?2025 (\$ million)

Exhibit 94 Global Premature Ejaculation Therapeutics Market by Geography 2019-2025 (%)

Exhibit 95 Premature Ejaculation Therapeutics Market in North America in 2019

Exhibit 96 North America Premature Ejaculation Therapeutics Market: Incremental & Absolute Growth

Exhibit 97 Premature Ejaculation Therapeutics Market in North America 2019-2025 (\$ million)

Exhibit 98 Incremental Growth by Drug Class 2019 & 2025

Exhibit 99 North America Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (\$ million)

Exhibit 100 North America Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (%)

Exhibit 101 Incremental Growth in North America 2019 & 2025

Exhibit 102 Number of People with Various Male Urologic Disorders in US

Exhibit 103 Premature Ejaculation Therapeutics Market in US 2019-2025 (\$ million)

Exhibit 104 Premature Ejaculation Therapeutics Market in Canada 2019-2025 (\$ million)

Exhibit 105 Premature Ejaculation Therapeutics Market in Europe 2019

Exhibit 106 Europe Premature Ejaculation Therapeutics Market: Incremental & Absolute Growth

Exhibit 107 Premature Ejaculation Therapeutics Market in Europe 2019-2025 (\$ million)

Exhibit 108 Incremental Growth by Drug Class 2019 & 2025

Exhibit 109 Europe Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (\$ million)

Exhibit 110 Europe Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (%)

Exhibit 111 Incremental Growth in Europe 2019 & 2025

Exhibit 112 Prevalence of PE in Men Aged 18-64 Years in Germany (%)

Exhibit 113 Premature Ejaculation Therapeutics Market in Germany 2019-2025 (\$ million)

Exhibit 114 Premature Ejaculation Therapeutics Market in UK 2019-2025 (\$ million)

Exhibit 115 Premature Ejaculation Therapeutics Market in France 2019-2025 (\$ million)

Exhibit 116 Premature Ejaculation Therapeutics Market in Italy 2019-2025 (\$ million)

Exhibit 117 Premature Ejaculation Therapeutics Market in Spain 2019-2025 (\$ million)

Exhibit 118 APAC Premature Ejaculation Therapeutics Market: Incremental & Absolute Growth

Exhibit 119 Premature Ejaculation Therapeutics Market in APAC 2019

Exhibit 120 Premature Ejaculation Therapeutics Market in APAC 2019-2025 (\$ million)

Exhibit 121 Incremental Growth by Drug Class 2019 & 2025

- Exhibit 122 APAC Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (\$ million)
- Exhibit 123 APAC Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (%)
- Exhibit 124 Incremental Growth in APAC 2019 & 2025
- Exhibit 125 Premature Ejaculation Therapeutics Market in Japan 2019–2025 (\$ million)
- Exhibit 126 Premature Ejaculation Therapeutics Market in India 2019–2025 (\$ million)
- Exhibit 127 Premature Ejaculation Therapeutics Market in China 2019–2025 (\$ million)
- Exhibit 128 Premature Ejaculation Therapeutics Market in Australia 2019–2025 (\$ million)
- Exhibit 129 Premature Ejaculation Therapeutics Market in South Korea 2019–2025 (\$ million)
- Exhibit 130 Premature Ejaculation Therapeutics Market in Latin America 2019
- Exhibit 131 Latin America Premature Ejaculation Therapeutics Market: Incremental & Absolute Growth
- Exhibit 132 Premature Ejaculation Therapeutics Market in Latin America 2019–2025 (\$ million)
- Exhibit 133 Incremental Growth by Drug Class 2019 & 2025
- Exhibit 134 Latin America Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (\$ million)
- Exhibit 135 Latin America Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (%)
- Exhibit 136 Incremental Growth in Latin America 2019 & 2025
- Exhibit 137 Premature Ejaculation Therapeutics Market in Brazil 2019–2025 (\$ million)
- Exhibit 138 Premature Ejaculation Therapeutics Market in Mexico 2019–2025 (\$ million)
- Exhibit 139 Premature Ejaculation Therapeutics Market in Argentina 2019–2025 (\$ million)
- Exhibit 140 Premature Ejaculation Therapeutics Market in MEA 2019
- Exhibit 141 MEA Premature Ejaculation Therapeutics Market: Incremental & Absolute Growth
- Exhibit 142 Premature Ejaculation Therapeutics Market in MEA 2019–2025 (\$ million)
- Exhibit 143 Incremental Growth by Drug Class 2019 & 2025
- Exhibit 144 MEA Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (\$ million)
- Exhibit 145 MEA Premature Ejaculation Therapeutics Market by Drug Class 2019-2025 (%)
- Exhibit 146 Incremental Growth in MEA 2019 & 2025
- Exhibit 147 Prevalence of PE in Turkish Population (%)
- Exhibit 148 Premature Ejaculation Therapeutics Market in Turkey 2019–2025 (\$ million)

Exhibit 149 Premature Ejaculation Therapeutics Market in Saudi Arabia 2019–2025 (\$ million)

Exhibit 150 Premature Ejaculation Therapeutics Market in South Africa 2019–2025 (\$ million)

Exhibit 151 Premature Ejaculation Therapeutics Market in Iran 2019–2025 (\$ million)

Exhibit 152 Global Premature Ejaculation Therapeutics Market: Vendors Market Share 2019

Exhibit 153 Pfizer: R&D Expenditure 2017?2019 (\$ million)

Exhibit 154 Pfizer: Revenue by Segments 2018 & 2019 (\$ million)

Exhibit 155 Pfizer: Revenue by Geography 2018 (%)

List Of Tables

LIST OF TABLES

Table 1 Key Caveats

Table 2 Currency Conversion 2013?2019

Table 3 Popular Definitions of Premature Ejaculation

Table 4 Summary of PE Epidemiology Studies

Table 5 Recommended/Optional Questions to Establish Diagnosis and Treatment of PE

Table 6 Summary of PE Validated Questionnaires

Table 7 Summary of Commonly Recommended PE Drugs

Table 8 Key Pipeline PE Drug Molecules

Table 9 Epelsiban: Product Profile

Table 10 IX-01 Product Profile

Table 11 DA-8031 Product Profile

Table 12 NH02D Product Profile

Table 13 Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules

Table 14 Key Topical Therapy PE Drugs by Type of Formulation

Table 15 Major Unmet Need in PE Market

Table 16 Marketed PE Drugs with Meter-Dose Delivery Systems

Table 17 Notable Awareness Campaigns Initiated for PE in Recent Years

Table 18 Key Terminated/Withdrawn & Inactive Investigational PE Drugs

Table 19 SSRIs Dose in PE Treatment

Table 20 List of Popular SSRIs for PE

Table 21 List of Popular PDE5 Inhibitors For PE

Table 22 Commonly Used Topical PE OTC Ester/Amide Anesthetic

Table 23 List of Popular Anesthetic Agents for Treating PE

Table 24 Significant Players Offering Oral Drugs for PE Treatment

Table 25 Comparison of Popular Topical Anesthetics for PE

Table 26 North America Premature Ejaculation Therapeutics Market by Drug Class
2019?2025 (\$ million)

Table 27 Key Campaigns Launched in Europe to Improve Awareness of PE

Table 28 Europe Premature Ejaculation Therapeutics Market by Drug Class 2019?2025
(\$ million)

Table 29 APAC Premature Ejaculation Therapeutics Market by Drug Class 2019?2025
(\$ million)

Table 30 Latin America Premature Ejaculation Therapeutics Market by Drug Class
2019?2025 (\$ million)

Table 31 MEA Premature Ejaculation Therapeutics Market by Drug Class 2019?2025 (\$

million)

Table 32 Competitive Structure Analysis of Global Premature Ejaculation Therapeutics Market 2019

Table 33 Global Premature Ejaculation Therapeutics Market Vendor Ranking 2019

Table 34 Absorption Pharmaceuticals: Major Product Offerings

Table 35 Innovus Pharmaceuticals: Major Product Offerings

Table 36 Pfizer: Major Product Offerings

Table 37 Plethora Solutions Holdings: Major Product Offerings

Table 38 Bayer: Major Product Offerings

Table 39 Eli Lilly and Company: Major Product Offerings

Table 40 GlaxoSmithKline: Major Product Offerings

Table 41 MidasCare: Major Product Offerings

Table 42 Momentum Management: Major Product Offerings

Table 43 Pound International: Major Product Offerings

Table 44 Reckitt Benckiser Group: Major Product Offerings

Table 45 Recordati: Major Product Offerings

Table 46 Royalty Pharma: Major Product Offerings

Table 47 Shibari: Major Product Offerings

Table 48 The Menarini Group: Major Product Offerings

Table 49 Global Premature Ejaculation Therapeutics Market by Drug Class 2019?2025 (\$ million)

Table 50 Global Premature Ejaculation Therapeutics Market by Drug Class 2019?2025 (%)

Table 51 Global Premature Ejaculation Therapeutics Market by ROA 2019?2025 (\$ million)

Table 52 Global Premature Ejaculation Therapeutics Market by ROA 2019?2025 (%)

Table 53 Global Premature Ejaculation Therapeutics Market by Geography 2019?2025 (\$ million)

Table 54 Global Premature Ejaculation Therapeutics Market by Geography 2019?2025 (%)

I would like to order

Product name: Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2020-2025

Product link: <https://marketpublishers.com/r/PB104A60A15EN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB104A60A15EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970